Sonja Haut has worked on impact valuation for Novartis since October 2015. Since May 2019 she has headed the Strategic Measurement and Materiality team in Global Health and Corporate Responsibility, now in Group Financial Reporting and Accounting. She is the driving force behind Novartis’s engagement in the Value Balancing Alliance and represents Novartis in the Impact Valuation Roundtable. She holds an MBA degree from IMD.
24 September 2021 • by John Elkington, Sonja Haut in Finance • 11 min read
Negative screening is well established among ESG and other impact investors, involving the avoidance of downside exposures, but the next generation will demand far more positive results. ...
Explore first person business intelligence from top minds curated for a global executive audience
Share